Giuseppe Gianini Figueiredo Leite
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Giuseppe Gianini Figueiredo Leite has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Reinaldo Salomão
Universidade Federal de Sao Paulo, Brasil
7 shared publications Hessel Peters-Sengers
Center for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam
3 shared publicationsMilena Karina Colo Brunialti
Division of Infectious Diseases, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil
3 shared publicationsTom van der Poll
National Science and Technology Institute for Precision Critical Care Medicine─INCT PCCM
3 shared publicationsAlexandre Keiji Tashima
Department of Biochemistry, Escola Paulista de Medicina, Universidade Federal de São Paulo
2 shared publicationsAugustijn M. Klarenbeek
Centre for Infection and Molecular Medicine (CIMM), Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
2 shared publications
Latest Publications
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (10)
Genomic Landscape and Clinical Actionability of Skin Adnexal Carcinomas
Purpose: Skin adnexal carcinomas (SACs) are rare and heterogeneous tumors with no established systemic treatment options and poor long-term survival rates in the advanced disease setting. Here, we aimed to characterize the genomic landscape and clinically actionable alterations across SAC subtypes. Methods: We analyzed next-generation sequencing data from SACs in the American Association for Cancer Research Project GENIE. Mutations, copy number alterations, and structural variants were annotated using OncoKB. Actionable alterations were defined as Level 1-2 alterations or tumor mutational burden (TMB) ≥10 mut/Mb. TMB was compared across subtypes and with melanoma, cutaneous squamous cell carcinoma (CSCC), and basal cell carcinoma (BCC). Results: A total of 224 SACs were analyzed (49% extramammary Paget disease [EMPD], 33% apocrine/eccrine, 17% sebaceous, 1% follicular). In EMPD, the most frequent actionable alterations were in PIK3CA (25.7%) and ERBB2 (22.9%). In sebaceous carcinoma, actionable alterations were mainly in KRAS (10.3%) and PIK3CA (10.3%). Apocrine/eccrine tumors also presented ERBB2 and PIK3CA alterations, but at lower frequencies (5.5% and 8.2%, respectively). TMB-high occurred in 10.1% of EMPD, 28.2% of sebaceous, and 21.9% of apocrine/eccrine tumors, lower than in melanoma (52.1%), CSCC (64.4%), and BCC (63.3%). SAC drivers showed important heterogeneity across subtypes. Overall, 48.2% of SACs harbored at least one potentially actionable alteration. Conclusion: SACs frequently harbor clinically actionable alterations in a histotype-dependent manner. The identification of lineage-specific genomic differences underscores the clinical and translational relevance of integrating histology with genomic profiling for guiding therapeutic decision making.
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (10)
Genomic Landscape and Clinical Actionability of Skin Adnexal Carcinomas
Purpose: Skin adnexal carcinomas (SACs) are rare and heterogeneous tumors with no established systemic treatment options and poor long-term survival rates in the advanced disease setting. Here, we aimed to characterize the genomic landscape and clinically actionable alterations across SAC subtypes. Methods: We analyzed next-generation sequencing data from SACs in the American Association for Cancer Research Project GENIE. Mutations, copy number alterations, and structural variants were annotated using OncoKB. Actionable alterations were defined as Level 1-2 alterations or tumor mutational burden (TMB) ≥10 mut/Mb. TMB was compared across subtypes and with melanoma, cutaneous squamous cell carcinoma (CSCC), and basal cell carcinoma (BCC). Results: A total of 224 SACs were analyzed (49% extramammary Paget disease [EMPD], 33% apocrine/eccrine, 17% sebaceous, 1% follicular). In EMPD, the most frequent actionable alterations were in PIK3CA (25.7%) and ERBB2 (22.9%). In sebaceous carcinoma, actionable alterations were mainly in KRAS (10.3%) and PIK3CA (10.3%). Apocrine/eccrine tumors also presented ERBB2 and PIK3CA alterations, but at lower frequencies (5.5% and 8.2%, respectively). TMB-high occurred in 10.1% of EMPD, 28.2% of sebaceous, and 21.9% of apocrine/eccrine tumors, lower than in melanoma (52.1%), CSCC (64.4%), and BCC (63.3%). SAC drivers showed important heterogeneity across subtypes. Overall, 48.2% of SACs harbored at least one potentially actionable alteration. Conclusion: SACs frequently harbor clinically actionable alterations in a histotype-dependent manner. The identification of lineage-specific genomic differences underscores the clinical and translational relevance of integrating histology with genomic profiling for guiding therapeutic decision making.
- Open Access
- 4 September 2026
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 25 (10) , 5230-5245
Sexual Dimorphism and Intraspecific Toxin Variation in Crotalus durissus terrificus Venom: Insights from Proteomics, Peptidomics, and Structural Modeling
The venom of the South American rattlesnake Crotalus durissus terrificus (Cdt) is renowned for its minimalist yet highly toxic arsenal. Intraspecific variability in expressed proteoforms and toxin content has been previously observed in Cdt venom, resulting in heterogeneous biological activities. In light of this, our study conducted an in-depth mass spectrometry-based analysis, combined with structural prediction to comprehensively assess Cdt venom variability and sexual dimorphism. Using peptidomic analysis, we identified 76 native peptides within Cdt venom, predominantly (63%) associated with noncanonical processing of crotoxin subunits, and 9 novel peptides via de novo sequencing. Quantitative analysis showed increased abundance of two crotapotin-derived peptides in females, while three novel peptides were significantly increased in males. Through quantitative proteomics, we characterized a repertoire of 33 proteins, with over one-third displaying sex-based differences in abundance. Furthermore, variant analysis revealed 12 novel toxin variants, generally at lower abundance than previously described proteoforms. Predictive three-dimensional structure modeling revealed conserved scaffolds, suggesting preservation of their biological activities. Addressing venom variability provides valuable insights into the intricate variability of Cdt venom, contributing to the understanding of its biological, medical, and biotechnological implications.
- 4 September 2026
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 25 (10) , 5230-5245
Open AccessSexual Dimorphism and Intraspecific Toxin Variation in Crotalus durissus terrificus Venom: Insights from Proteomics, Peptidomics, and Structural Modeling
The venom of the South American rattlesnake Crotalus durissus terrificus (Cdt) is renowned for its minimalist yet highly toxic arsenal. Intraspecific variability in expressed proteoforms and toxin content has been previously observed in Cdt venom, resulting in heterogeneous biological activities. In light of this, our study conducted an in-depth mass spectrometry-based analysis, combined with structural prediction to comprehensively assess Cdt venom variability and sexual dimorphism. Using peptidomic analysis, we identified 76 native peptides within Cdt venom, predominantly (63%) associated with noncanonical processing of crotoxin subunits, and 9 novel peptides via de novo sequencing. Quantitative analysis showed increased abundance of two crotapotin-derived peptides in females, while three novel peptides were significantly increased in males. Through quantitative proteomics, we characterized a repertoire of 33 proteins, with over one-third displaying sex-based differences in abundance. Furthermore, variant analysis revealed 12 novel toxin variants, generally at lower abundance than previously described proteoforms. Predictive three-dimensional structure modeling revealed conserved scaffolds, suggesting preservation of their biological activities. Addressing venom variability provides valuable insights into the intricate variability of Cdt venom, contributing to the understanding of its biological, medical, and biotechnological implications.
- Open Access
- 1 August 2026
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 25 (9) , 4380-4392
Proteins as Regulators of Metabolic Changes in Sepsis: Alterations in Body Fluids, Immune Cells, and Organs through the Eyes of Proteomics
Sepsis is a life-threatening syndrome characterized by a dysregulated host response to infection and profound metabolic alterations that contribute to immune dysfunction and organ failure. This Review synthesizes proteomic evidence on sepsis-associated alterations in proteins involved in metabolic pathways across circulating biofluids, immune cells, and organs. Across plasma and urine, proteomic studies identify disturbances in lipoprotein-associated pathways, redox homeostasis, mitochondrial function, and substrate metabolism, indicating that protein signatures of metabolic dysregulation are systemic and detectable across biofluids. In immune cells, monocytes and neutrophils, proteomic analyses reveal a shift toward glycolysis with concurrent impairment of mitochondrial pathways alongside phenotype-dependent differences in lipid and redox-related programs. Organ-level studies further show that metabolic responses are heterogeneous, with distinct trajectories in the kidney, heart, liver, lung, skeletal muscle, and brain. These observations support the concept that sepsis involves compartment-specific remodeling of metabolism-associated protein networks rather than a single convergent metabolic state. Proteomics also highlights potential translational opportunities by identifying metabolism-associated proteins linked to disease severity, clinical phenotypes, and biologically distinct patient subgroups, although the current evidence remains largely exploratory and context-dependent. Overall, proteomics provides a complementary framework for understanding the molecular regulation of sepsis-associated metabolic dysfunction and may refine biological stratification and therapeutic targeting, particularly when integrated with longitudinal sampling and multiomic data.
- 1 August 2026
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 25 (9) , 4380-4392
Open AccessProteins as Regulators of Metabolic Changes in Sepsis: Alterations in Body Fluids, Immune Cells, and Organs through the Eyes of Proteomics
Sepsis is a life-threatening syndrome characterized by a dysregulated host response to infection and profound metabolic alterations that contribute to immune dysfunction and organ failure. This Review synthesizes proteomic evidence on sepsis-associated alterations in proteins involved in metabolic pathways across circulating biofluids, immune cells, and organs. Across plasma and urine, proteomic studies identify disturbances in lipoprotein-associated pathways, redox homeostasis, mitochondrial function, and substrate metabolism, indicating that protein signatures of metabolic dysregulation are systemic and detectable across biofluids. In immune cells, monocytes and neutrophils, proteomic analyses reveal a shift toward glycolysis with concurrent impairment of mitochondrial pathways alongside phenotype-dependent differences in lipid and redox-related programs. Organ-level studies further show that metabolic responses are heterogeneous, with distinct trajectories in the kidney, heart, liver, lung, skeletal muscle, and brain. These observations support the concept that sepsis involves compartment-specific remodeling of metabolism-associated protein networks rather than a single convergent metabolic state. Proteomics also highlights potential translational opportunities by identifying metabolism-associated proteins linked to disease severity, clinical phenotypes, and biologically distinct patient subgroups, although the current evidence remains largely exploratory and context-dependent. Overall, proteomics provides a complementary framework for understanding the molecular regulation of sepsis-associated metabolic dysfunction and may refine biological stratification and therapeutic targeting, particularly when integrated with longitudinal sampling and multiomic data.
- Open Access
- 7 April 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 366, 121658
Phytochemical characterization and toxicological evaluation of Myrciaria pilosa leaf essential oil using experimental and computational strategies
- 7 April 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 366, 121658
Open AccessPhytochemical characterization and toxicological evaluation of Myrciaria pilosa leaf essential oil using experimental and computational strategies
- Open Access
- 2 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1815841
Editorial: The impact of proteomics on understanding inflammatory and infectious diseases
Inflammatory and infectious diseases remain major global health challenges, affecting millions of individuals and imposing a sustained burden on healthcare systems. A mechanistic understanding of how host responses interact with pathogens and inflammatory triggers in tissue microenvironments is essential for improving diagnosis, prognosis, and treatment. With the increasing sensitivity, speed, and robustness of modern mass spectrometry platforms, shotgun proteomics has become a central systems-level approach for interrogating these diseases at molecular depth. By quantifying proteins and their modifications, proteomics often offers a more direct window into disease mechanisms than for example transcriptomics. This Research Topic highlights the transformative power of proteomics and multiomics in decoding the molecular landscapes of complex human diseases. From acute viral infections and fungal sepsis to chronic autoimmune disorders, the collected articles demonstrate how systematic characterization of the proteome -including post-translational modifications (PTMs) and extracellular vesicle (EV) cargo -can identify potential biomarkers for diagnosis, prognosis, and therapeutic monitoring. The scientific rationale for this collection is grounded in the urgent need for pathogenagnostic, host response-based strategies to address clinical challenges in which traditional diagnostic tools often fail to provide early or personalized predictive insights.A first set of studies focuses on the critical need for prognostic biomarkers to guide clinical management of high-mortality infectious diseases. These studies address translational challenges: early discrimination of clinical trajectories and long-term risk.In severe fever with thrombocytopenia syndrome, a proteasome-centered serum proteomic signature identified through machine-learning models prioritized PSMD11 as a robust predictor of adverse outcomes (Zhao et al., 2025). Similarly, longitudinal plasma profiling in an Ethiopian COVID-19 cohort identified SLAMF1, IL15RA, and IL18 as key markers that not only define acute severity but also predict the risk of postacute sequelae (Long COVID) (Wolday et al., 2025). These findings emphasize the transition from broad descriptive proteomics to focused predictive panels adaptable to diverse clinical settings. In addition, these works are especially relevant because longitudinal molecular studies in underrepresented populations remain scarce.At the diagnostic level, Mnichowska-Polanowska et al., (2025), demonstrated that multiplex proximity extension proteomics, a targeted high-throughput approach for measure many proteins simultaneously, can distinguish isolated candidemia from mixed bacterial-fungal sepsis through a compact inflammatory signature (including LAP-TGF-β1, TRANCE, and IL-17C), a distinction with direct implications for antimicrobial stewardship and treatment personalization. Together, these studies exemplify how proteomics coupled to analytical modeling can support risk stratification beyond conventional inflammatory markers.A second axis of the Topic addresses extracellular vesicles (EVs), which have emerged as a pivotal focus for biomarker discovery and mechanistic insight. In visceral leishmaniasis (VL), a severe parasitic infection caused by Leishmania parasites, the proteomic landscape of plasma-derived EVs revealed 132 human proteins differentially expressed during therapy (Torres et al., 2025). Notably, serum amyloid A (SAA) emerged as a measurable whole-plasma biomarker for monitoring treatment success. Furthermore, the identification of Leishmania proteins within human EV samples provides a novel source of parasite-specific biomarkers for monitoring clinical remission (Torres et al., 2025).In the context of COVID-19, circulating EVs from patients with severe disease were enriched in platelet components and molecular signals that exacerbate innate immune-driven inflammation (Strippoli et al., 2026). This study provided a possible link between EV protein cargo and the enhanced responsiveness of Vδ2 T cells, contributing to the pathogenesis of severe infection (Strippoli et al., 2026).The collection also explores the pathophysiological basis of chronic inflammatory diseases. Tissue-level proteomics of intestinal biopsies in ulcerative colitis revealed a dual pathophysiological nature: an exacerbated inflammatory state coupled with substantial metabolic dysfunction, specifically the downregulation of proteins involved in oxidative phosphorylation and the citric acid cycle (Wang et al., 2025). A similar convergence on fundamental cellular machinery is seen in ankylosing spondylitis, a chronic inflammatory arthritis, where ribosomal proteins (e.g., RPS11, RPS6) in hipjoint tissues were identified as hub nodes linked to osteoblast differentiation and T celljoint damage (Wen et al., 2025).Multi-omics integration is exemplified in rheumatoid arthritis (RA) by Zhang et al., (2025), who combined serum proteomics and metabolomics and identified the FBP1/AMPK axis as a key regulator of disease activity. Their integrative analysis also provided a plausible mechanistic explanation for the effects of Qingre Huoxue Decoction: in RA patients and in collagen-induced arthritis mice models, treatment was associated with reduced disease activity, attenuated inflammatory responses, and delayed bone destruction, potentially through FBP1 inhibition and AMPK activation.Finally, this Topic includes an important conceptual bridge between mechanistic virology and therapeutic innovation. In a comprehensive review, Li et al. (2005) synthesize how proteome-wide characterization of post-translational modifications (PTMs) illuminates host-virus interactions and identifies putative antiviral drug targets.The broader implication is straightforward: if infection outcomes are shaped by dynamic protein states rather than static abundance alone, then PTM-aware proteomics becomes indispensable for...
- 2 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1815841
Open AccessEditorial: The impact of proteomics on understanding inflammatory and infectious diseases
Inflammatory and infectious diseases remain major global health challenges, affecting millions of individuals and imposing a sustained burden on healthcare systems. A mechanistic understanding of how host responses interact with pathogens and inflammatory triggers in tissue microenvironments is essential for improving diagnosis, prognosis, and treatment. With the increasing sensitivity, speed, and robustness of modern mass spectrometry platforms, shotgun proteomics has become a central systems-level approach for interrogating these diseases at molecular depth. By quantifying proteins and their modifications, proteomics often offers a more direct window into disease mechanisms than for example transcriptomics. This Research Topic highlights the transformative power of proteomics and multiomics in decoding the molecular landscapes of complex human diseases. From acute viral infections and fungal sepsis to chronic autoimmune disorders, the collected articles demonstrate how systematic characterization of the proteome -including post-translational modifications (PTMs) and extracellular vesicle (EV) cargo -can identify potential biomarkers for diagnosis, prognosis, and therapeutic monitoring. The scientific rationale for this collection is grounded in the urgent need for pathogenagnostic, host response-based strategies to address clinical challenges in which traditional diagnostic tools often fail to provide early or personalized predictive insights.A first set of studies focuses on the critical need for prognostic biomarkers to guide clinical management of high-mortality infectious diseases. These studies address translational challenges: early discrimination of clinical trajectories and long-term risk.In severe fever with thrombocytopenia syndrome, a proteasome-centered serum proteomic signature identified through machine-learning models prioritized PSMD11 as a robust predictor of adverse outcomes (Zhao et al., 2025). Similarly, longitudinal plasma profiling in an Ethiopian COVID-19 cohort identified SLAMF1, IL15RA, and IL18 as key markers that not only define acute severity but also predict the risk of postacute sequelae (Long COVID) (Wolday et al., 2025). These findings emphasize the transition from broad descriptive proteomics to focused predictive panels adaptable to diverse clinical settings. In addition, these works are especially relevant because longitudinal molecular studies in underrepresented populations remain scarce.At the diagnostic level, Mnichowska-Polanowska et al., (2025), demonstrated that multiplex proximity extension proteomics, a targeted high-throughput approach for measure many proteins simultaneously, can distinguish isolated candidemia from mixed bacterial-fungal sepsis through a compact inflammatory signature (including LAP-TGF-β1, TRANCE, and IL-17C), a distinction with direct implications for antimicrobial stewardship and treatment personalization. Together, these studies exemplify how proteomics coupled to analytical modeling can support risk stratification beyond conventional inflammatory markers.A second axis of the Topic addresses extracellular vesicles (EVs), which have emerged as a pivotal focus for biomarker discovery and mechanistic insight. In visceral leishmaniasis (VL), a severe parasitic infection caused by Leishmania parasites, the proteomic landscape of plasma-derived EVs revealed 132 human proteins differentially expressed during therapy (Torres et al., 2025). Notably, serum amyloid A (SAA) emerged as a measurable whole-plasma biomarker for monitoring treatment success. Furthermore, the identification of Leishmania proteins within human EV samples provides a novel source of parasite-specific biomarkers for monitoring clinical remission (Torres et al., 2025).In the context of COVID-19, circulating EVs from patients with severe disease were enriched in platelet components and molecular signals that exacerbate innate immune-driven inflammation (Strippoli et al., 2026). This study provided a possible link between EV protein cargo and the enhanced responsiveness of Vδ2 T cells, contributing to the pathogenesis of severe infection (Strippoli et al., 2026).The collection also explores the pathophysiological basis of chronic inflammatory diseases. Tissue-level proteomics of intestinal biopsies in ulcerative colitis revealed a dual pathophysiological nature: an exacerbated inflammatory state coupled with substantial metabolic dysfunction, specifically the downregulation of proteins involved in oxidative phosphorylation and the citric acid cycle (Wang et al., 2025). A similar convergence on fundamental cellular machinery is seen in ankylosing spondylitis, a chronic inflammatory arthritis, where ribosomal proteins (e.g., RPS11, RPS6) in hipjoint tissues were identified as hub nodes linked to osteoblast differentiation and T celljoint damage (Wen et al., 2025).Multi-omics integration is exemplified in rheumatoid arthritis (RA) by Zhang et al., (2025), who combined serum proteomics and metabolomics and identified the FBP1/AMPK axis as a key regulator of disease activity. Their integrative analysis also provided a plausible mechanistic explanation for the effects of Qingre Huoxue Decoction: in RA patients and in collagen-induced arthritis mice models, treatment was associated with reduced disease activity, attenuated inflammatory responses, and delayed bone destruction, potentially through FBP1 inhibition and AMPK activation.Finally, this Topic includes an important conceptual bridge between mechanistic virology and therapeutic innovation. In a comprehensive review, Li et al. (2005) synthesize how proteome-wide characterization of post-translational modifications (PTMs) illuminates host-virus interactions and identifies putative antiviral drug targets.The broader implication is straightforward: if infection outcomes are shaped by dynamic protein states rather than static abundance alone, then PTM-aware proteomics becomes indispensable for...
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500709
Development and Validation of an Intratumor Heterogeneity–Based Prognostic Model for Clear Cell Renal Cell Carcinoma
PURPOSE: Clear cell renal cell carcinoma (ccRCC) is characterized by marked intratumor heterogeneity (ITH), which contributes to therapeutic resistance and poor clinical outcomes. We aimed to develop a robust prognostic model for stratifying patients with ccRCC on the basis of ITH. METHODS: RNA-seq data from 522 patients with ccRCC in TCGA-KIRC were analyzed using the DEPTH algorithm to quantify ITH, with external validation in the E-MTAB-1980 cohort (N = 101). Differentially expressed genes between high and low DEPTH tumors were identified, and a machine learning framework was applied to develop the ITHscore. The ITHscore was compared with other published signatures in literature for ccRCC. RESULTS: The random survival forest model on the basis of three genes ( UBE2C , MOCOS , and MELTF ) was selected to compose the ITHscore, showing high accuracy in the development (5-year AUC = 0.957) and in the validation cohorts (5-year AUC = 0.82). The ITHscore had the best performance across all 45 retrieved signatures in both development and validation data sets. High-ITHscore tumors exhibited immunosuppressive microenvironments and were associated with immune checkpoint blockade (ICB) resistance signatures. The ITHscore was significantly associated with poor overall survival in five distinct tumor types across a meta-analysis of 104 independent data sets comprising 18,004 patients. CONCLUSION: We developed and validated the ITHscore, a three-gene expression–based model with superior prognostic performance in ccRCC. The ITHscore reflects key features of aggressiveness in tumor biology, including immune evasion and ICB resistance. Its minimal gene set and consistent performance across data sets support its potential for clinical implementation in ccRCC stratification.
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500709
Development and Validation of an Intratumor Heterogeneity–Based Prognostic Model for Clear Cell Renal Cell Carcinoma
PURPOSE: Clear cell renal cell carcinoma (ccRCC) is characterized by marked intratumor heterogeneity (ITH), which contributes to therapeutic resistance and poor clinical outcomes. We aimed to develop a robust prognostic model for stratifying patients with ccRCC on the basis of ITH. METHODS: RNA-seq data from 522 patients with ccRCC in TCGA-KIRC were analyzed using the DEPTH algorithm to quantify ITH, with external validation in the E-MTAB-1980 cohort (N = 101). Differentially expressed genes between high and low DEPTH tumors were identified, and a machine learning framework was applied to develop the ITHscore. The ITHscore was compared with other published signatures in literature for ccRCC. RESULTS: The random survival forest model on the basis of three genes ( UBE2C , MOCOS , and MELTF ) was selected to compose the ITHscore, showing high accuracy in the development (5-year AUC = 0.957) and in the validation cohorts (5-year AUC = 0.82). The ITHscore had the best performance across all 45 retrieved signatures in both development and validation data sets. High-ITHscore tumors exhibited immunosuppressive microenvironments and were associated with immune checkpoint blockade (ICB) resistance signatures. The ITHscore was significantly associated with poor overall survival in five distinct tumor types across a meta-analysis of 104 independent data sets comprising 18,004 patients. CONCLUSION: We developed and validated the ITHscore, a three-gene expression–based model with superior prognostic performance in ccRCC. The ITHscore reflects key features of aggressiveness in tumor biology, including immune evasion and ICB resistance. Its minimal gene set and consistent performance across data sets support its potential for clinical implementation in ccRCC stratification.
- Open Access
- 28 October 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (6) , 2500335
The proteomic landscape of blood monocytes in community-acquired pneumonia
Introduction: Monocytes play a pivotal role in the regulation of inflammation and pathogen clearance during infection. Knowledge of the human monocyte proteome during infection is limited. We present a comprehensive proteome profile of blood monocytes from patients with community-acquired pneumonia (CAP), one of the most common infectious diseases, and controls without infection. Methods: Monocytes were purified from blood of patients with CAP within 16 h of admission to a general hospital ward and from controls matched for sex, age and comorbidities. Monocyte proteins were measured using liquid chromatography/mass spectrometry. The transcriptome was analysed in the same samples by RNA sequencing. Monocytes were stimulated with lipopolysaccharide for 24 h, after which cytokines were measured in the supernatant. Results: We analysed the monocyte proteome of 34 CAP patients and 23 controls. Out of 7315 annotated proteins, 1340 (18.3%) were differentially abundant between groups. Functional enrichment analyses revealed a marked downregulation of mitochondrial respiration processes in patient monocytes; pathways pertaining to cell cycle, cytokine signalling and cell death were upregulated in patient monocytes. Monocyte mRNA levels correlated poorly with the abundance of corresponding proteins and associated functional pathways, raising caution regarding interpretation of functionality estimates based on transcriptome analyses. Differential expression of monocyte proteins had functional and clinical implications as indicated by associations with cytokine production capacity, disease severity and time to clinical stability. Conclusion: This study provides a publicly available monocyte protein atlas that can serve as a resource for future research on monocyte functions during infection.
- 28 October 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (6) , 2500335
Open AccessThe proteomic landscape of blood monocytes in community-acquired pneumonia
Introduction: Monocytes play a pivotal role in the regulation of inflammation and pathogen clearance during infection. Knowledge of the human monocyte proteome during infection is limited. We present a comprehensive proteome profile of blood monocytes from patients with community-acquired pneumonia (CAP), one of the most common infectious diseases, and controls without infection. Methods: Monocytes were purified from blood of patients with CAP within 16 h of admission to a general hospital ward and from controls matched for sex, age and comorbidities. Monocyte proteins were measured using liquid chromatography/mass spectrometry. The transcriptome was analysed in the same samples by RNA sequencing. Monocytes were stimulated with lipopolysaccharide for 24 h, after which cytokines were measured in the supernatant. Results: We analysed the monocyte proteome of 34 CAP patients and 23 controls. Out of 7315 annotated proteins, 1340 (18.3%) were differentially abundant between groups. Functional enrichment analyses revealed a marked downregulation of mitochondrial respiration processes in patient monocytes; pathways pertaining to cell cycle, cytokine signalling and cell death were upregulated in patient monocytes. Monocyte mRNA levels correlated poorly with the abundance of corresponding proteins and associated functional pathways, raising caution regarding interpretation of functionality estimates based on transcriptome analyses. Differential expression of monocyte proteins had functional and clinical implications as indicated by associations with cytokine production capacity, disease severity and time to clinical stability. Conclusion: This study provides a publicly available monocyte protein atlas that can serve as a resource for future research on monocyte functions during infection.
- 3 March 2025
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 117 (4)
Characterizing a low-density neutrophil gene signature in acute and chronic infections and its impact on disease severity
Low-density neutrophils (LDNs) or polymorphonuclear myeloid-derived suppressor cells are involved in the pathogenesis of cancer, autoimmune, and infectious diseases. They are crucial in the host response to invading pathogens, especially during acute illness, and are associated with poor prognosis in many infectious diseases. However, their gene expression profile and contribution to disease outcomes are not well described. We conducted a meta-analysis of gene expression datasets from peripheral blood mononuclear cells (PBMCs), focusing on patients with viral and bacterial infections. We identified a consensus set of 2,798 differentially expressed genes. Among these, 49 genes were commonly found in both the neutrophil degranulation pathway and the granule lumen-specific community. To validate this signature, we evaluated its expression in RNA-seq datasets, finding consistent upregulation of 24 genes in severe infections, 17 of them overlapped with genes overexpressed in CD16int cells. We also investigated the abundance of LDN-related proteins in a PBMC proteomics dataset from a cohort of sepsis and septic shock patients. Out of the 17 genes analyzed, 13 corresponding proteins were identified, 10 of which demonstrated significantly higher abundance in sepsis and septic shock patients compared with healthy controls. In conclusion, our study identified a pattern of 17 upregulated LDN genes, common to PBMC transcriptome and RNA-seq, and upregulated in CD16int, associated with acute infections and severe clinical outcomes, marking the first time these genes have been collectively presented as a potential signature of LDNs in relation to disease severity. Further research with prospective cohorts is needed to validate this LDN signature and explore its clinical implications.
- 3 March 2025
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 117 (4)
Characterizing a low-density neutrophil gene signature in acute and chronic infections and its impact on disease severity
Low-density neutrophils (LDNs) or polymorphonuclear myeloid-derived suppressor cells are involved in the pathogenesis of cancer, autoimmune, and infectious diseases. They are crucial in the host response to invading pathogens, especially during acute illness, and are associated with poor prognosis in many infectious diseases. However, their gene expression profile and contribution to disease outcomes are not well described. We conducted a meta-analysis of gene expression datasets from peripheral blood mononuclear cells (PBMCs), focusing on patients with viral and bacterial infections. We identified a consensus set of 2,798 differentially expressed genes. Among these, 49 genes were commonly found in both the neutrophil degranulation pathway and the granule lumen-specific community. To validate this signature, we evaluated its expression in RNA-seq datasets, finding consistent upregulation of 24 genes in severe infections, 17 of them overlapped with genes overexpressed in CD16int cells. We also investigated the abundance of LDN-related proteins in a PBMC proteomics dataset from a cohort of sepsis and septic shock patients. Out of the 17 genes analyzed, 13 corresponding proteins were identified, 10 of which demonstrated significantly higher abundance in sepsis and septic shock patients compared with healthy controls. In conclusion, our study identified a pattern of 17 upregulated LDN genes, common to PBMC transcriptome and RNA-seq, and upregulated in CD16int, associated with acute infections and severe clinical outcomes, marking the first time these genes have been collectively presented as a potential signature of LDNs in relation to disease severity. Further research with prospective cohorts is needed to validate this LDN signature and explore its clinical implications.
- Open Access
- 23 January 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 65 (4) , 2400592
The blood transcriptional response in patients developing intensive care unit-acquired pneumonia
Background: Immune response dysregulation has been implicated in the development of intensive care unit (ICU)-acquired pneumonia. We aimed to determine differences in the longitudinal blood transcriptional response between patients who develop ICU-acquired pneumonia (cases) and those who do not (controls).Methods: We performed a case–cohort study in mechanically ventilated trauma and surgery patients with ICU stays >2 days, enrolled in 30 hospitals across Europe. We collected blood for RNA sequencing at baseline, day 7 and (in cases) the day of pneumonia diagnosis. We performed gene set enrichment analysis and analysed longitudinal gene expression changes using linear mixed models. External validation was performed using an independent trauma cohort.Results: We enrolled 113 cases and 115 controls, with similar baseline characteristics. At baseline (median 2 days after ICU admission), cases showed upregulated gene pathways relating to innate immunity, haemostasis and metabolism, and downregulated adaptive immune pathways. These changes persisted at the day of pneumonia diagnosis (median 6 days, compared to day 7 in controls). In the longitudinal comparison, cases exhibited enhanced upregulation of innate immunity, adaptive immunity and haemostasis pathways, along with enhanced downregulation of metabolism pathways, relative to controls (all p<0.00001, except haemostasis p<0.05). These findings were largely externally validated. Cases had higher quantitative sepsis response signature scores (p<0.001), reflective of immune dysregulation.Conclusion: Patients developing ICU-acquired pneumonia exhibit distinct blood transcriptional responses shortly after ICU admission and in the subsequent path to pneumonia, suggestive of broad immune dysfunction with both immunosuppressive and inflammatory features.
- 23 January 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 65 (4) , 2400592
Open AccessThe blood transcriptional response in patients developing intensive care unit-acquired pneumonia
Background: Immune response dysregulation has been implicated in the development of intensive care unit (ICU)-acquired pneumonia. We aimed to determine differences in the longitudinal blood transcriptional response between patients who develop ICU-acquired pneumonia (cases) and those who do not (controls).Methods: We performed a case–cohort study in mechanically ventilated trauma and surgery patients with ICU stays >2 days, enrolled in 30 hospitals across Europe. We collected blood for RNA sequencing at baseline, day 7 and (in cases) the day of pneumonia diagnosis. We performed gene set enrichment analysis and analysed longitudinal gene expression changes using linear mixed models. External validation was performed using an independent trauma cohort.Results: We enrolled 113 cases and 115 controls, with similar baseline characteristics. At baseline (median 2 days after ICU admission), cases showed upregulated gene pathways relating to innate immunity, haemostasis and metabolism, and downregulated adaptive immune pathways. These changes persisted at the day of pneumonia diagnosis (median 6 days, compared to day 7 in controls). In the longitudinal comparison, cases exhibited enhanced upregulation of innate immunity, adaptive immunity and haemostasis pathways, along with enhanced downregulation of metabolism pathways, relative to controls (all p<0.00001, except haemostasis p<0.05). These findings were largely externally validated. Cases had higher quantitative sepsis response signature scores (p<0.001), reflective of immune dysregulation.Conclusion: Patients developing ICU-acquired pneumonia exhibit distinct blood transcriptional responses shortly after ICU admission and in the subsequent path to pneumonia, suggestive of broad immune dysfunction with both immunosuppressive and inflammatory features.
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 58, e14960
Tracking immune dysregulation in COVID-19: lymphocyte dynamics from hospitalization to recovery
A hallmark of COVID-19 patients is the reduction of the lymphocyte population accompanied by activation, senescence, and exhaustion markers. We investigated patients admitted to hospital wards who either recovered after a short hospitalization or progressed to critical illness. Patients (n=48) were recruited between May and September 2020; 19 healthy volunteers were enrolled as controls. Blood samples were collected on days 0, 3, and 7 of hospitalization and around 30 days after discharge (convalescence sample, CS30). Lymphocyte counts and extended immunophenotyping were performed by flow cytometry and analyzed using conventional and stochastic methods. At D0 and D7, total lymphocytes, natural killer cells, T cells, TCD4 cells, and TCD8 cells were lower in patients than in volunteers but were restored at CS30. The stochastic analysis identified 11 distinct clusters of lymphocytes, nine of them with significant differences between patients and healthy controls. Clusters of TCD8+ memory cells showing activation, senescence, and exhaustion were increased in patients during hospitalization and in the convalescence samples. In contrast, clusters 5 (TCD4+ Central Memory exhausted activated) and 7 (TCD4+ Central Memory exhausted) were decreased in patients during the disease compared to healthy controls. Overall, the conventional flow cytometry analyses corroborated the findings from the stochastic analysis, showing that effector memory (EM) and TEMRA subsets exhibited sustained markers of exhaustion and senescence, particularly in TCD8+ cells. Our findings reinforce lymphopenia, T cell activation, senescence, and exhaustion as essential immunological features of COVID-19; while cell counts fully recovered, lymphocytes remained dysfunctional in convalescent samples.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 58, e14960
Open AccessTracking immune dysregulation in COVID-19: lymphocyte dynamics from hospitalization to recovery
A hallmark of COVID-19 patients is the reduction of the lymphocyte population accompanied by activation, senescence, and exhaustion markers. We investigated patients admitted to hospital wards who either recovered after a short hospitalization or progressed to critical illness. Patients (n=48) were recruited between May and September 2020; 19 healthy volunteers were enrolled as controls. Blood samples were collected on days 0, 3, and 7 of hospitalization and around 30 days after discharge (convalescence sample, CS30). Lymphocyte counts and extended immunophenotyping were performed by flow cytometry and analyzed using conventional and stochastic methods. At D0 and D7, total lymphocytes, natural killer cells, T cells, TCD4 cells, and TCD8 cells were lower in patients than in volunteers but were restored at CS30. The stochastic analysis identified 11 distinct clusters of lymphocytes, nine of them with significant differences between patients and healthy controls. Clusters of TCD8+ memory cells showing activation, senescence, and exhaustion were increased in patients during hospitalization and in the convalescence samples. In contrast, clusters 5 (TCD4+ Central Memory exhausted activated) and 7 (TCD4+ Central Memory exhausted) were decreased in patients during the disease compared to healthy controls. Overall, the conventional flow cytometry analyses corroborated the findings from the stochastic analysis, showing that effector memory (EM) and TEMRA subsets exhibited sustained markers of exhaustion and senescence, particularly in TCD8+ cells. Our findings reinforce lymphopenia, T cell activation, senescence, and exhaustion as essential immunological features of COVID-19; while cell counts fully recovered, lymphocytes remained dysfunctional in convalescent samples.